The Challenging Morbidity, Risk, and Therapeutic Continuum of MAC Lung Disease<br><sub>What Have We Learned from the ERS Treatment Guideline, Real World Experience, and Recent Trials Focused on High Risk/Refractory MAC Lung Disease?</sub>

Video

The Challenging Morbidity, Risk, and Therapeutic Continuum of MAC Lung Disease
_{What Have We Learned from the ERS Treatment Guideline, Real World Experience, and Recent Trials Focused on High Risk/Refractory MAC Lung Disease?}

Name: The Challenging Morbidity, Risk, and Therapeutic Continuum of MAC Lung Disease<br><sub>What Have We Learned from the ERS Treatment Guideline, Real World Experience, and Recent Trials Focused on High Risk/Refractory MAC Lung Disease?</sub>
Uploaded: 2022-08-31T00:00:00+00:00

Overview

Continue to Test Back to Symposium

Published

August 31, 2022

Created by

Related Presenters

Professor Christoph Lange, MD - Program Chair

Medical Director/Clinical Director
Research Center Borstel
Borstel, Germany

The Challenging Morbidity, Risk, and Therapeutic Continuum of MAC Lung DiseaseWhat Have We Learned from the ERS Treatment Guideline, Real World Experience, and Recent Trials Focused on High Risk/Refractory MAC Lung Disease?

The Challenging Morbidity, Risk, and Therapeutic Continuum of MAC Lung Disease
_{What Have We Learned from the ERS Treatment Guideline, Real World Experience, and Recent Trials Focused on High Risk/Refractory MAC Lung Disease?}